• Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Gari, M.A., Peake, I.R., Rees, D.C., Vandenberghe, E.A., Winship, P.R. & Reilly, J.T. (2000) FLT3 internal tandem duplication mutations in adult myeloid leukaemia define a high risk group. British Journal of Haematology, 111, 190195.
  • Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Care, R.S., Peake, I.R. & Reilly, J.T. (2001) Identification of novel FLT3 Asp835 mutations in adult acute myeloid leukaemia. British Journal of Haematology, 113, 983988.
  • Beghini, A., Cairoli, R., Morra, E. & Larizza, L. (1998) In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation. Blood Cells, Molecules, and Diseases, 24, 262270.
  • Beghini, A., Peterlongo, P., Ripamonti, C.B., Larizza, L., Cairoli, R., Morra, E. & Mecucci, C. (2000) c-kit mutations in core binding factor leukemias. Blood, 95, 726727.
  • Castilla, L.H., Garrett, L., Adya, N., Orlie, D., Dutra, A., Anderson, S., Owens, J., Eckhaus, M., Bodine, D. & Liu, P.P. (1999) The fusion gene CBFb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukemia. Nature Genetics, 23, 144146.
  • Gari, M., Goodeve, A., Wilson, G., Winship, P., Langabeer, S., Linch, D., Vandenberghe, E., Peake, I. & Reilly, J. (1999) c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. British Journal of Haematology, 105, 894900.
  • Gilliland, D.G. (2001) Hematologic malignancies. Current Opinions in Hematology, 8, 189191.
  • Kaplan, E.L. & Meier, P. (1958) Non parametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457481.
  • Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy analysis of 854 patients from the United Kingdom Research Council AML 10 and 12 trials. Blood, 98, 17521759.
  • Mantel, N. & Haenszel, W. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute, 22, 719748.
  • Reilly, J.T. (2002) Class III receptor tyrosine kinases: role in leukaemogenesis. British Journal of Haematology, 116, 744757.
  • Yuan, Y., Zhou, L., Miyamoto, T., Iwasaki, H., Harakawa, N., Hetherington, C.J., Burel, S.A., Lagasse, E., Weissman, I.L., Akashi, K. & Zhang, D.E. (2001) AML1-ETO expression is directly involved in the development of acute myeloid leukaemia in the presence of additional mutations. Proceedings of the National Academy of Sciences of the United States of America, 98, 1039810403.